202 related articles for article (PubMed ID: 38570452)
1. Crystallographic Studies of KRAS in Complex with Small Molecules and RAS-Binding Proteins.
Chan AH; Simanshu DK
Methods Mol Biol; 2024; 2797():47-65. PubMed ID: 38570452
[TBL] [Abstract][Full Text] [Related]
2. Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention.
Johnson C; Burkhart DL; Haigis KM
Cancer Discov; 2022 Apr; 12(4):913-923. PubMed ID: 35373279
[TBL] [Abstract][Full Text] [Related]
3. KRAS: From undruggable to a druggable Cancer Target.
Uprety D; Adjei AA
Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
[TBL] [Abstract][Full Text] [Related]
4. Discovery and biological evaluation of 1-{2,7-diazaspiro[3.5]nonan-2-yl}prop-2-en-1-one derivatives as covalent inhibitors of KRAS G12C with favorable metabolic stability and anti-tumor activity.
Imaizumi T; Akaiwa M; Abe T; Nigawara T; Koike T; Satake Y; Watanabe K; Kaneko O; Amano Y; Mori K; Yamanaka Y; Nagashima T; Shimazaki M; Kuramoto K
Bioorg Med Chem; 2022 Oct; 71():116949. PubMed ID: 35926326
[TBL] [Abstract][Full Text] [Related]
5. Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies.
Shetu SA; Bandyopadhyay D
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409064
[TBL] [Abstract][Full Text] [Related]
6. Ras protein abundance correlates with Ras isoform mutation patterns in cancer.
Hood FE; Sahraoui YM; Jenkins RE; Prior IA
Oncogene; 2023 Apr; 42(15):1224-1232. PubMed ID: 36864243
[TBL] [Abstract][Full Text] [Related]
7. Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers.
Mattox TE; Chen X; Maxuitenko YY; Keeton AB; Piazza GA
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31878223
[TBL] [Abstract][Full Text] [Related]
8. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
Holderfield M; Lee BJ; Jiang J; Tomlinson A; Seamon KJ; Mira A; Patrucco E; Goodhart G; Dilly J; Gindin Y; Dinglasan N; Wang Y; Lai LP; Cai S; Jiang L; Nasholm N; Shifrin N; Blaj C; Shah H; Evans JW; Montazer N; Lai O; Shi J; Ahler E; Quintana E; Chang S; Salvador A; Marquez A; Cregg J; Liu Y; Milin A; Chen A; Ziv TB; Parsons D; Knox JE; Klomp JE; Roth J; Rees M; Ronan M; Cuevas-Navarro A; Hu F; Lito P; Santamaria D; Aguirre AJ; Waters AM; Der CJ; Ambrogio C; Wang Z; Gill AL; Koltun ES; Smith JAM; Wildes D; Singh M
Nature; 2024 May; 629(8013):919-926. PubMed ID: 38589574
[TBL] [Abstract][Full Text] [Related]
9. KRAS
Zhou ZW; Ambrogio C; Bera AK; Li Q; Li XX; Li L; Son J; Gondi S; Li J; Campbell E; Jin H; Okoro JJ; Xu CX; Janne PA; Westover KD
Cancer Res; 2020 Sep; 80(17):3719-3731. PubMed ID: 32605999
[TBL] [Abstract][Full Text] [Related]
10. Membrane-Driven Dimerization of the Peripheral Membrane Protein KRAS: Implications for Downstream Signaling.
Lee KY
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473778
[TBL] [Abstract][Full Text] [Related]
11. RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics.
Kattan WE; Hancock JF
Biochem J; 2020 Aug; 477(15):2893-2919. PubMed ID: 32797215
[TBL] [Abstract][Full Text] [Related]
12. Targeting the RAS-dependent chemoresistance: The Warburg connection.
Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
[TBL] [Abstract][Full Text] [Related]
13. Ras and exosome signaling.
Sexton RE; Mpilla G; Kim S; Philip PA; Azmi AS
Semin Cancer Biol; 2019 Feb; 54():131-137. PubMed ID: 30769101
[TBL] [Abstract][Full Text] [Related]
14. Strategies for Targeting KRAS: A Challenging Drug Target.
Wadood A; Ajmal A; Rehman AU
Curr Pharm Des; 2022; 28(23):1897-1901. PubMed ID: 35524675
[TBL] [Abstract][Full Text] [Related]
15. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.
Hunter JC; Manandhar A; Carrasco MA; Gurbani D; Gondi S; Westover KD
Mol Cancer Res; 2015 Sep; 13(9):1325-35. PubMed ID: 26037647
[TBL] [Abstract][Full Text] [Related]
17. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
[TBL] [Abstract][Full Text] [Related]
18. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
Nussinov R; Zhang M; Tsai CJ; Jang H
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
[TBL] [Abstract][Full Text] [Related]
19. Therapeutics Targeting Mutant KRAS.
Thein KZ; Biter AB; Hong DS
Annu Rev Med; 2021 Jan; 72():349-364. PubMed ID: 33138715
[TBL] [Abstract][Full Text] [Related]
20. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
Roskoski R
Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
